Amylyx Pharmaceuticals reported a pivotal Phase 3 success for avexitide (a GLP-1 receptor antagonist) in post-bariatric hypoglycemia (PBH), announcing a 55% reduction in the rate of serious hypoglycemic events versus placebo in the Lucidity trial. The study was powered to demonstrate a 35% improvement and met statistical significance. Amylyx said the results support a potential regulatory path as an initial therapy option for PBH, a rare but high-risk endocrine complication after bariatric surgery. The company framed the magnitude of event reduction as clinically meaningful for patients and families managing unpredictable severe lows. With the top-line readout, Amylyx is positioning for broader uptake if approved, while continuing to prepare the next steps for submissions and launch planning.